


Fig. 2

Fig. 3

		Cancer		Cancer		Cancer		Cancer		Cancer		Cancer		Cancer		
		Krebs	Cluster 1	Krebs	Cluster 2	Krebs	Cluster 3	T-Test	T-Test	T-Test	T-Test	T-Test	T-Test	C1 / C2	C1 / C3	
1	Lectin; galactose-binding	4.4 +/- 2.5	32.2 +/- 8.1	58.8 +/- 6.5	97.81	96.16	99.97							0	50	100
2	M-FABP	7.6 +/- 4.0	35.7 +/- 12.7	44.4 +/- 4.3	91.99	49.62	99.55									
3	microsemitoprotein	16.6 +/- 3.5	36.6 +/- 2.9	51.5 +/- 4.5	99.90	98.23	99.95									
4	n.i.	23.1 +/- 1.5	41.8 +/- 8.3	53.6 +/- 6.5	78.96	58.11	95.46									
5	Isopeptidase T	25.6 +/- 2.2	2.2 +/- 1.6	22.4 +/- 6.6	99.99	91.72	31.40									
6	Serum Amyloid P Comptone	56.2 +/- 2.5	15.4 +/- 6.2	22.4 +/- 6.5	99.85	53.14	99.63									
7	Transferrin	62.4 +/- 7.4	27.8 +/- 9.7	44.7 +/- 8.4	97.76	73.12	82.74									
8	n.i.	37.5 +/- 9.4	34.5 +/- 4.9	51.3 +/- 9.4	23.88	83.99	58.11									
9	n.i.	45.3 +/- 7.6	38.1 +/- 1.7	49.5 +/- 8.8	72.64	83.07	25.93									
10	nuclear chloride ion channel	48.4 +/- 2.5	60.1 +/- 4.9	74.5 +/- 7.1	90.84	86.75	98.73									
11	n.i.	50.4 +/- 4.1	62.3 +/- 4.4	41.3 +/- 9.5	83.55	93.41	48.63									
12	triosephosphate isomerase	50.3 +/- 2.0	62.8 +/- 4.6	48.7 +/- 3.5	93.46	95.59	26.32									
13	biliverdin reductase B	53.2 +/- 6.9	63.3 +/- 4.3	49.0 +/- 8.0	75.56	79.52	27.12									
14	n.i.	42.6 +/- 11.0	63.7 +/- 3.6	52.7 +/- 3.4	94.89	91.91	57.87									
15	aldolase A [Homo sapiens]	47.4 +/- 3.1	66.2 +/- 5.0	41.2 +/- 8.0	98.14	97.96	45.28									
16	n.i.	53.6 +/- 3.5	66.7 +/- 4.0	56.9 +/- 3.4	94.59	88.75	45.06									
17	aldolase A [Homo sapiens]	49.0 +/- 9.1	66.9 +/- 3.7	49.4 +/- 3.5	94.15	98.92	3.40									
18	14-3-3 beta	49.2 +/- 2.0	67.1 +/- 3.8	56.1 +/- 3.5	99.68	92.46	89.90									
19	n.i.	49.0 +/- 2.4	67.6 +/- 6.6	44.7 +/- 4.1	96.33	97.53	54.05									
20	n.i.	46.1 +/- 4.5	67.8 +/- 5.4	48.7 +/- 3.2	98.20	98.16	34.24									
21	14-3-3 zeta	52.7 +/- 2.6	67.9 +/- 3.6	50.5 +/- 2.1	98.61	99.68	47.20									
22	n.i.	36.9 +/- 8.0	73.1 +/- 3.8	48.9 +/- 10.8	99.84	97.07	55.60									
23	n.i.	50.1 +/- 5.2	76.9 +/- 4.3	56.6 +/- 2.1	99.70	99.28	66.31									
24	14-3-3 tau	54.9 +/- 4.3	77.8 +/- 3.9	55.2 +/- 2.8	98.71	99.89	4.08									
25	heat shock protein 90	56.0 +/- 9.1	82.0 +/- 5.7	62.1 +/- 1.5	95.78	95.59	36.32									
26	annexin A3	56.4 +/- 13.0	83.3 +/- 4.9	52.0 +/- 14.4	89.39	88.03	14.65									
27	prolyl 4-hydroxylase beta 5	55.0 +/- 6.5	83.9 +/- 3.3	60.0 +/- 3.0	99.93	99.88	41.95									
28	enoyl-coenzyme A hydratase	68.2 +/- 6.4	84.2 +/- 3.9	71.4 +/- 8.3	95.08	79.35	21.82									
29	E-FABP	57.9 +/- 13.0	84.4 +/- 9.7	64.2 +/- 12.5	84.84	74.74	23.75									
30	Similar to nucleophosmin	87.7 +/- 1.8	86.0 +/- 7.9	62.1 +/- 24.2	11.36	65.71	54.05									
31	heat shock protein 27	39.9 +/- 3.1	39.2 +/- 6.2	40.6 +/- 1.2	6.87	14.28	15.32									

Fig. 4

Protein	no. Pat.	no. Obs.	Benign		Cancer		StdErr	T-Test	chan	0	50	100
			Demographic	Fraction	Demographic	Fraction						
Isopeptidase T	21	12	83.6	5.2	16.4	5.0	100.0	-5.1				
Serum Amyloid P Component	21	19	73.1	5.8	26.9	5.8	100.0	-2.7				
M-FABP	21	8	71.6	8.3	28.4	8.3	100.0	-2.5				
Lectin; galactose-binding	21	14	66.2	7.1	33.8	7.1	100.0	-2.0				
microseminoprotein	21	20	63.9	4.1	36.1	4.1	100.0	-1.8				
n.i.	19	12	60.6	5.3	39.5	5.3	100.0	-1.5				
heat shock protein 27	21	20	60.2	3.7	39.8	3.7	100.0	-1.5				
14-3-3 beta	21	21	41.2	3.0	58.8	3.0	100.0	-1.5				
14-3-3 zeta	21	20	41.1	3.3	58.9	3.0	100.0	-1.4				
n.i.	21	21	40.1	3.8	59.9	3.8	100.0	-1.4				
annexin A3	21	20	39.5	3.3	60.5	3.3	100.0	-1.5				
14-3-3 tau	21	15	35.8	8.2	64.2	7.8	98.5	1.8	0			
heat shock protein 90	21	20	35.6	3.7	64.4	3.7	100.0	1.8				
Prolyl 4-hydroxylase beta subunit	21	13	32.6	6.4	67.4	6.4	100.0	2.1				
E-FABP	21	19	31.2	4.5	68.8	4.4	100.0	2.2				
enoyl-coenzyme S hydratase	21	13	27.9	7.7	72.1	7.7	100.0	2.6				
Similar to nucleophosmin	21	18	26.2	4.6	73.8	4.5	100.0	2.8				
	21	12	21.9	9.1	78.1	7.2	100.0	3.6				

Fig. 5




Fig. 6




Fig. 7a




Fig. 7b




Fig. 7c




Fig. 8




Fig. 9

No.	Protein Name	Accession Nr.	PMF score	31 Patients			22/31 Patients			9/31 Patients		
				P-value	0	50	100	P-value	0	50	100	P-value
1	IsoT	gi 1732411	115	<0.0001	■■■■■	■■■■■	■■■■■	0.0006	■■■■■	■■■■■	■■■■■	0.0300
2	SAP	gi 576259	106*	0.0001	■■■■■	■■■■■	■■■■■	0.0005	■■■■■	■■■■■	■■■■■	0.1398
3	M-FABP	gi 494781	87	0.0048	■■■■■	■■■■■	■■■■■	0.0069	■■■■■	■■■■■	■■■■■	0.4640
4	Galectin-1	gi 4504981	177*	0.0124	■■■■■	■■■■■	■■■■■	0.0106	■■■■■	■■■■■	■■■■■	0.4400
5	HSP 27	gi 662841	182*	0.0007	■■■■■	■■■■■	■■■■■	0.0071	■■■■■	■■■■■	■■■■■	0.0050
6	microsemionoprotein	gi 225159	92*	0.0002	■■■■■	■■■■■	■■■■■	0.0002	■■■■■	■■■■■	■■■■■	0.1602
7	Rho GDI	gi 4757768	150	0.0011	■■■■■	■■■■■	■■■■■	0.0005	■■■■■	■■■■■	■■■■■	0.9058
8	14-3-3 zeta	gi 4507953	160*	0.0009	■■■■■	■■■■■	■■■■■	0.0003	■■■■■	■■■■■	■■■■■	0.6951
9	14-3-3 beta	gi 4507949	160*	0.0016	■■■■■	■■■■■	■■■■■	0.0008	■■■■■	■■■■■	■■■■■	0.8253
10	HSP 90, alpha	gi 13129150	147	0.0006	■■■■■	■■■■■	■■■■■	0.0005	■■■■■	■■■■■	■■■■■	0.4506
	HSP 90, beta	gi 20149594	164									
11	14-3-3 tau	gi 5803227	130*	0.0028	■■■■■	■■■■■	■■■■■	0.0028	■■■■■	■■■■■	■■■■■	0.2661
12	BIP/HspA5	gi 87528	273	0.1551	■■■■■	■■■■■	■■■■■	0.0075	■■■■■	■■■■■	■■■■■	0.1843
13	PDI	gi 20070125	235	<0.0001	■■■■■	■■■■■	■■■■■	<0.0001	■■■■■	■■■■■	■■■■■	0.4575
14	annexin A3	gi 4826643	160	0.0453	■■■■■	■■■■■	■■■■■	0.0008	■■■■■	■■■■■	■■■■■	0.5030
15	E-FABP	gi 4557581	94*	0.0009	■■■■■	■■■■■	■■■■■	0.0010	■■■■■	■■■■■	■■■■■	0.4807
16	enoyl-co A hydratase	gi 12707570	101*	<0.0001	■■■■■	■■■■■	■■■■■	<0.0001	■■■■■	■■■■■	■■■■■	0.2054
17	nucleophosmin	gi 16307090	77	0.0015	■■■■■	■■■■■	■■■■■	0.0001	■■■■■	■■■■■	■■■■■	0.8401

Fig. 10

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record.**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.